Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. SPINRAZA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

SPINRAZA

Medicine - Posted on Jul 10 2024
Active substance (DCI)
  • nusinersen
history (3)
  • 7/3/24

    SPINRAZA (nusinersen) - Spinal muscular atrophy

    Summary of opinion Favourable opinion for reimbursement: “in pre-symptomatic paediatric patients with genetically diagnosed ...
    CAV :
    54321
    icône flèche
  • 7/22/20

    SPINRAZA

    New assessment. Favourable opinion for reimbursement in the treatment of pre-symptomatic infants and children with genetical...
    CAV :
    54321
    icône flèche
  • Economic analysis
    1/31/18

    SPINRAZA (nusinersen), antisense oligonucleotide

    High clinical benefit for 5q spinal muscular atrophy types I and II and moderate clinical added value for the therapeutic st...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • M09AX07
Manufacturer
BIOGEN FRANCE SAS
Presentation

SPINRAZA 12 mg, solution injectable (code CIS : 65599882)
1 flacon(s) en verre de 5 ml (CIP : 34009 550 331 5 8)

All our publications
    Congenital, genetic and rare diseases Drug therapy Health economics Neurodegenerative diseases Neuromuscular diseases Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mF1v2jAUhu/5FVHuSaCUtUyBamNlQ2pVRkGbdlOZ5FDMgp0e23z0188hVEsnR10NvoztvD72ef34yNHVdpV6a0BBOev6zaDhe8BinlD22PWnk0H90r/q1aIlWZPSsIugETTPfC9OiRBdP+8NZkCYCH7e3nwB/T+g36t5EZ8tIZavxilJ0+AbEYtbkuVjvGjNaeKtQC540vUzJfetXiQk6ih6G46/RUZiiMJDS7l3+XBebo/CXOw/VJUAvCHs0SgKzEozVojAZJ9IeOS4q4i3ZaVNxRgEVxjDiMjFCPmaJpAYp5iTVIDVJPNNcg+4TkHmkxjFw2W8ElbiZEm2Y3gamoP+pHv7civrjXrz4rzTaLc7rVa7ZbdZWNoqcxb0IsIsw+ThrHPZanUuQmChyChD8kws8zPiKEnqKDNU9F+by9E8CE9vOiChIkvJLliKzHarCBLdDagR4G4h+QomqKGU6j37R5+pNA3fGfX0gAxHEedE6nPFZAU5BmPbjehzJmFbnVE72MntwYsUxOlknzkzg36kZimNbbGmwaNAyOl4WE21UwPhMxEwRXdE+EFZwjfi9KQpZ9ZR9NkelkZRnYRmnoUPzXbb+iD90jaquGmuFfIMQs0gKo5By5DN+bFQ0c40S7348qSW3Nc8PCYpVFQ9dUvGaC++FGnO3O7uJBUdRtGv1xNbi3xXgLv7/adRmibdcnLtGOwC7NqTlbG/3+HFQXdSEis0A2QhZSY+huFmswkWRNQF0bsUzNEJ5Et3q7ui3MkFXhQ0BSgdhT4rbsD3Zcn2wL11xR9bth7+P5THxjkkKjgiFwWbnRF0eH16KP+tWZ2FPXpFEHfT7OtLIilnrmoeNTMXPMdeAzq1bICaEXfzOa14J6m0ZhQWbzS9WhTm7zO92h+Q3O7X
HE7fPvWLdUrV4NbP